Hiv Prevention Study
Posted Date: Jun 17, 2021
- Investigator: Moises Huaman
- Specialties:
- Type of Study: Drug
A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People = 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection
Criteria:
Null
Keywords:
Hiv, Prevention
For More Information:
Sharon Kohrs, Rn
513-584-6383
kohrssd@ucmail.uc.edu